Allarity Therapeutics: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR PR Newswire NEW YORK, July 25, 2023 NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" ...
Publicerad: 2023-07-26 00:21 av PR Newswire
Allarity Therapeutics: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR PR Newswire NEW YORK, July 17, 2023 NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" ...
Publicerad: 2023-07-17 23:19 av PR Newswire
Allarity Therapeutics: Thinking about buying stock in Lucid Group, OPKO Health, Eos Energy Enterprises, Kartoon Studios, or Allarity Therapeutics? PR Newswire NEW YORK, July 6, 2023 NEW YORK , July 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, OPK, EOSE, TOON, and ALLR. To see how I ...
Publicerad: 2023-07-06 15:31 av PR Newswire
Allarity Therapeutics: Thinking about buying stock in Helbiz, General Electric, Allarity Therapeutics, Bed Bath & Beyond, or Lucid Group? PR Newswire NEW YORK, Jan. 23, 2023 NEW YORK , Jan. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HLBZ, GE, ALLR, BBBY, and LCID. To see how Investors ...
Publicerad: 2023-01-23 16:53 av PR Newswire
Allarity Therapeutics: EQS-News: Allarity Therapeutics, Inc. Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform 18.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Once brought into its pipeline, Allarity uses its ...
Publicerad: 2022-10-18 14:00 av EQS Newswire
Allarity Therapeutics Inc: Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that o ...
Publicerad: 2022-04-22 23:00 av GlobeNewswire
Allarity Therapeutics Inc: FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA Allarity intends to announce the results of the Type ...
Publicerad: 2022-03-15 13:32 av GlobeNewswire
Allarity Therapeutics Inc: Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) t ...
Publicerad: 2022-01-03 14:00 av GlobeNewswire
Allarity Therapeutics: Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”) has accepted the Company’s application to delist the shares of Allarity A/S. Allarity A/S submitted th ...
Publicerad: 2021-12-13 23:00 av GlobeNewswire
Allarity Therapeutics: Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliatio ...
Publicerad: 2021-12-11 15:35 av GlobeNewswire
Allarity Therapeutics: Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the "Offer"), with the intent of completing the Company's ...
Publicerad: 2021-11-24 23:15 av GlobeNewswire
Allarity Therapeutics: Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the authorization granted by the shareholders at the Extraordinary General Meeting held on November 22, 2021, to ...
Publicerad: 2021-11-24 21:50 av GlobeNewswire
Allarity Therapeutics: Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September 2021. The report is available as an attached document and on the company’s website. Steve Carchedi, C ...
Publicerad: 2021-11-23 08:00 av GlobeNewswire
Allarity Therapeutics: Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of ...
Publicerad: 2021-11-23 00:00 av GlobeNewswire
Allarity Therapeutics: Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant), and gamma variant P.1 (“Brazilian” variant). Allarity Therapeutics is planning to submit findings t ...
Publicerad: 2021-11-11 08:30 av GlobeNewswire
Allarity Therapeutics: Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am Central European Time at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, DK-1256 C ...
Publicerad: 2021-11-05 22:11 av GlobeNewswire
Allarity Therapeutics: An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the Company’s Recapitalization Share Exchange The Recapitalization Share Exchange of the Company is subject to app ...
Publicerad: 2021-11-05 21:48 av GlobeNewswire
Allarity Therapeutics: Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical development The agreement meets Allarity’s needs for current and future commercial production of dovitinib and will support the Company’s planned NDA filing in ...
Publicerad: 2021-09-23 09:00 av GlobeNewswire
Allarity Therapeutics: Patient selection using DRP® score of 50% resulted in a median survival of 15.0 month Patient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced ...
Publicerad: 2021-09-16 10:00 av GlobeNewswire
Allarity Therapeutics: Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press ReleaseHørsholm, Denmark (September 15, 2021) CORRECTION: The press release that the company published on S ...
Publicerad: 2021-09-15 23:55 av GlobeNewswire
Allarity Therapeutics: Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press Release Hørsholm, Denmark (September 14, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) to ...
Publicerad: 2021-09-14 23:06 av GlobeNewswire
Allarity Therapeutics: 31 August 2021 ALLARITY THERAPEUTICS A/S On 31 August 2021 at 13:00 (CEST), an extraordinary general meeting of shareholders (the "General Meeting") of Allarity Therapeutics A/S, company registration (CVR) no. 28 10 63 51 (the "Company"), was held at c/o Mazanti-Andersen Advokatpartnerselskab, Amali ...
Publicerad: 2021-08-31 21:19 av GlobeNewswire
Allarity Therapeutics: Press Release Hørsholm, Denmark (August 26, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces that an accelerated extraordinary and final exercise period for warrants of the ALLR TO 3 series (the “TO 3 Warrants”), which were issued to subscribers of units in the Company ...
Publicerad: 2021-08-26 08:32 av GlobeNewswire
Allarity Therapeutics: Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth quarter, 2021 A previously-announced U.S. $20 million investment by 3i Fund supports Company’s transition to the U.S. Nasdaq Press releaseHørsholm, Denmark (August 23, 2021) — Allarity Therapeutics A/S (“Allarity” ...
Publicerad: 2021-08-23 08:45 av GlobeNewswire
Allarity Therapeutics: Press ReleaseHørsholm, Denmark (August 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – June 2021. The report is available as an attached document and on the Company’s website. Steve Carchedi, CEO of Al ...
Publicerad: 2021-08-23 07:00 av GlobeNewswire
Allarity Therapeutics: Press ReleaseHørsholm, Denmark (August 19, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a new publication date for the Company’s Q2 2021 Interim Report, which is now being made public on August 23, 2021 (previously: August 31, 2021). The reason for the change of pu ...
Publicerad: 2021-08-19 21:45 av GlobeNewswire
Allarity Therapeutics: Press Release Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to convene an Extraordinary General Meeting on August 31, 2021. The Company hereby further elaborates on the information provided in the notice. Based on questions ...
Publicerad: 2021-08-18 08:26 av GlobeNewswire
Allarity Therapeutics: 16 August 2021 ALLARITY THERAPEUTICS A/S31 AUGUST 2021 AT 13:00 (CET) The Board of Directors hereby convenes an Extraordinary General Meeting of Allarity Therapeutics A/S, company registration (CVR) no. 28106351 (the "Company"), to be held on 31 August 2021 at 13:00 (CET) at c/o Mazanti-Andersen Adv ...
Publicerad: 2021-08-16 23:18 av GlobeNewswire
Allarity Therapeutics: Current positive results with 3 variants, including alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant) and gamma variant P.1 (“Brazilian” variant), follows prior pre-clinical tests indicating efficacy of the novel PARP inhibitor stenoparib against SARS-Cov-2 All ...
Publicerad: 2021-08-05 13:00 av GlobeNewswire
Allarity Therapeutics: Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) – Allarity Therapeutics A/S (“Allarity”) and Lantern Pharma Inc. (“Lantern” ...
Publicerad: 2021-07-26 08:30 av GlobeNewswire